

Mattias Mandorfer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8296455/publications.pdf>

Version: 2024-02-01

307
papers

7,271
citations

76326

40
h-index

76900

74
g-index

332
all docs

332
docs citations

332
times ranked

5526
citing authors

#	ARTICLE	IF	CITATIONS
1	Baveno VII “Renewing consensus in portal hypertension. <i>Journal of Hepatology</i> , 2022, 76, 959-974.	3.7	890
2	Nonselective β_2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2014, 146, 1680-1690.e1.	1.3	336
3	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
4	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 911-921.	3.7	269
5	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , 2016, 65, 692-699.	3.7	245
6	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
7	HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. <i>Journal of Hepatology</i> , 2017, 66, 282-287.	3.7	154
8	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
9	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy “ development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	3.7	132
10	Beta adrenergic blockade and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2017, 66, 849-859.	3.7	127
11	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020, 71, 1023-1036.	7.3	112
12	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015, 35, 381-390.	3.9	111
13	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 135-158.	1.9	111
14	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 723-732.	0.4	105
15	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	12.1	100
16	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
17	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	3.7	96
18	Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 139-149.	3.7	83

#	ARTICLE	IF	CITATIONS
19	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , 2019, 157, 705-719.e18.	1.3	82
20	Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 980-988.	3.7	78
21	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015, 35, 2121-2128.	3.9	72
22	Where does TIPS fit in the management of patients with cirrhosis?. <i>JHEP Reports</i> , 2020, 2, 100122.	4.9	72
23	Gut-liver axis signaling in portal hypertension. <i>World Journal of Gastroenterology</i> , 2019, 25, 5897-5917.	3.3	67
24	Beta blockers and cirrhosis, 2016. <i>Digestive and Liver Disease</i> , 2017, 49, 3-10.	0.9	64
25	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*Z vs Pi*MZ). <i>Journal of Hepatology</i> , 2020, 72, 113-120.	1.3	63
26	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
27	Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease. <i>Liver Transplantation</i> , 2018, 24, 744-751.	2.4	58
28	HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. <i>Journal of Hepatology</i> , 2020, 73, 113-120.	3.7	58
29	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. <i>PLoS ONE</i> , 2014, 9, e110503.	2.5	55
30	Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. <i>Liver International</i> , 2015, 35, 2115-2120.	3.9	54
31	HCV targeting of patients with cirrhosis. <i>Journal of Hepatology</i> , 2015, 63, 1015-1022.	3.7	54
32	Does the Functional Liver Imaging Score Derived from Gadoteric Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease?. <i>Radiology</i> , 2020, 294, 98-107.	7.3	51
33	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	12.1	51
34	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	51
35	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , 2016, 10, 424-435.	4.2	47
36	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 2374-2385.	3.9	47

#	ARTICLE	IF	CITATIONS
37	Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020, 40, 240-255.	3.6	46
38	Response to guided long-term treatment of chronic hepatitis D patients with bulevirtide: results of a real world study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 144-154.	3.7	46
39	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 194-204.	3.9	45
40	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
41	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. <i>Hepatology</i> , 2022, 76, 1563-1575.	7.3	45
42	Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 707-718.	3.7	44
43	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 8-15.	1.9	44
44	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016, 30, 1039-1047.	2.2	42
45	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	4.4	42
46	Fazirsiran for Liver Disease Associated with Alpha ₁ -Antitrypsin Deficiency. <i>New England Journal of Medicine</i> , 2022, 387, 514-524.	27.0	42
47	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 966-979.	3.7	41
48	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.9	41
49	Low vitamin D levels are associated with impaired virologic response to PEGIFN α 2a+ α 2b therapy in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2013, 27, 227-232.	2.2	39
50	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 127-135.	3.9	39
51	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	4.4	39
52	Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment: Is It Worth Measuring?. <i>Current Hepatology Reports</i> , 2019, 18, 174-186.	0.9	38
53	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1657-1665.	2.8	37
54	EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs. <i>Disease Markers</i> , 2017, 2017, 1-9.	1.3	37

#	ARTICLE	IF	CITATIONS
55	Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 86-94.	3.7	36
56	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	3.9	36
57	Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014, 34, 69-77.	3.9	35
58	Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1162-1169.	3.7	33
59	Revisiting liver disease progression in HIV/HCV co-infected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , 2015, 35, 876-885.	3.9	32
60	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018, 38, 1427-1436.	3.9	31
61	Outcomes after placement of a SXLLEA oesophageal stent for refractory variceal bleeding: A national multicentre study. <i>Liver International</i> , 2019, 39, 290-298.	3.9	30
62	Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	3.8	30
63	Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. <i>PLoS ONE</i> , 2016, 11, e0152910.	2.5	30
64	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108544.	2.5	29
65	Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G484-G494.	3.4	29
66	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , 2017, 49, 1360-1367.	0.9	28
67	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	3.9	28
68	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	12.1	28
69	Transferrin as a predictor of survival in cirrhosis. <i>Liver Transplantation</i> , 2018, 24, 343-351.	2.4	27
70	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2020, 40, 2797-2807.	3.9	27
71	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	3.9	27
72	Impact of patatin-like phospholipase domain containing rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 451-459.	3.7	26

#	ARTICLE	IF	CITATIONS
73	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	3.7	26
74	Reversion and Conversion of Interferon- β Release Assay Results in HIV-1â€“Infected Individuals. <i>Journal of Infectious Diseases</i> , 2014, 209, 729-733.	4.0	25
75	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	4.4	25
76	Prevention of First Decompensation in Advanced Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2021, 25, 291-310.	2.1	25
77	IFNL4 rs469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014, 9, e95515.	2.5	24
78	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2340-2349.	1.5	23
79	Liver disease in adults with α -1 antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	3.8	23
80	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019, 51, 1144-1151.	0.9	23
81	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0143429.	2.5	23
82	Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. <i>Gut</i> , 2017, 66, 1347-1349.	12.1	22
83	High efficacy of interferonâ€“free therapy for acute hepatitis C in HIVâ€“positive patients. <i>United European Gastroenterology Journal</i> , 2019, 7, 507-516.	3.8	22
84	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acuteâ€“onâ€“chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	3.8	22
85	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	3.9	21
86	Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0116768.	2.5	21
87	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding â€“ A two decades experience. <i>PLoS ONE</i> , 2018, 13, e0189414.	2.5	20
88	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	3.9	20
89	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. <i>United European Gastroenterology Journal</i> , 2021, 9, 1119-1127.	3.8	20
90	Inter- and intra-reader agreement for gadoxetic acidâ€“enhanced MRI parameter readings in patients with chronic liver diseases. <i>European Radiology</i> , 2019, 29, 6600-6610.	4.5	19

#	ARTICLE	IF	CITATIONS
91	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022, 4, 100513.	4.9	19
92	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. <i>Gut</i> , 2023, 72, 381-391.	12.1	19
93	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. <i>Medicine (United States)</i> , 2016, 95, e4061.	1.0	18
94	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 850-858.	3.8	18
95	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 533-542.	5.1	18
96	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2022, 75, 610-622.	7.3	18
97	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 184-190.	2.8	17
98	Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?. <i>Current Hepatology Reports</i> , 2018, 17, 301-315.	0.9	17
99	The Addition of C-reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease—Sodium Improves Prediction of Waitlist Mortality. <i>Hepatology</i> , 2021, 74, 1533-1545.	7.3	17
100	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2019, 49, 201-211.	3.4	16
101	Hepatitis C Virus RNA Is Commonly Detectable in Rectal and Nasal Fluids of Patients With High Viremia. <i>Clinical Infectious Diseases</i> , 2020, 71, 1292-1299.	5.8	16
102	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	4.3	16
103	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021, 16, e0256544.	2.5	16
104	Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2318-2326.e7.	4.4	16
105	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. <i>Liver International</i> , 2022, 42, 2501-2512.	3.9	16
106	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 2707-2714.	2.2	15
107	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 1-11.	1.9	15
108	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. <i>Liver International</i> , 2022, 42, 1297-1307.	3.9	15

#	ARTICLE	IF	CITATIONS
109	Viral determinants predicting hepatitis B surface antigen (HBsAg) seroclearance in HIV/HBV/HCV coinfecting patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 508-516.	2.0	14
110	Effects of Portal Hypertension on Gadolinium-Enhanced Liver Magnetic Resonance. <i>Investigative Radiology</i> , 2017, 52, 462-469.	6.2	14
111	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 105-114.	1.9	14
112	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	3.9	14
113	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <i>Liver International</i> , 2020, 40, 787-796.	3.9	14
114	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2021, 15, 922-933.	4.2	14
115	Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). <i>Journal of Hepatology</i> , 2016, 64, 1452-1454.	3.7	13
116	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-8.	1.5	13
117	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 395-403.	1.9	13
118	Revisiting predictors of virologic response to PEGIFN+RBV therapy in HIV/HCV/HCV coinfecting patients: the role of metabolic factors and elevated GGT levels. <i>Journal of Viral Hepatitis</i> , 2014, 21, 33-41.	2.0	12
119	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015, 10, e0125080.	2.5	12
120	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	4.2	12
121	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1619-1627.	2.8	12
122	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	4.2	12
123	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	4.4	12
124	Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227.	2.5	11
125	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	1.5	11
126	Recent outbreaks of severe hepatitis A virus infections in Vienna. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 335-344.	2.9	11

#	ARTICLE	IF	CITATIONS
127	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2022, 54, 500-508.	0.9	11
128	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2022, 57, 99-110.	5.1	11
129	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 729-735.	4.0	10
130	The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , 2016, 36, 1649-1656.	3.9	10
131	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019, 14, e0224506.	2.5	10
132	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019, 33, 197-206.	2.5	10
133	The Renaissance of Cholemic Nephropathy: A Likely Underestimated Cause of Renal Dysfunction in Liver Disease. <i>Hepatology</i> , 2019, 69, 1858-1860.	7.3	10
134	Outcomes of an HCV elimination program targeting the Viennese MSM population. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 635-640.	1.9	10
135	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1264.	2.5	10
136	The “Viennese epidemic” of acute HCV in the era of direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2022, 29, 385-394.	2.0	10
137	The Influence of Portal Pressure on the Discordance Between Absolute CD4+ Cell Count and CD4+ Cell Percentage in HIV/Hepatitis C Virus-Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2013, 56, 904-905.	5.8	9
138	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 517-526.	1.9	9
139	Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response. <i>Gastroenterology</i> , 2018, 154, 1550-1551.	1.3	9
140	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	2.8	9
141	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. <i>Hepatology International</i> , 2020, 14, 1083-1092.	4.2	9
142	Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , 2020, 40, 2228-2241.	3.9	9
143	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	2.3	8
144	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2020, 12, 2961.	3.7	8

#	ARTICLE	IF	CITATIONS
145	Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography. <i>Ultraschall in Der Medizin</i> , 2023, 44, 169-178.	1.5	8
146	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. <i>Journal of Hepatology</i> , 2022, 77, 1005-1013.	3.7	8
147	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.8	7
148	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , 2019, 7, 651-661.	3.8	7
149	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	3.4	7
150	Direct patient-physician communication via a hepatitis hotline facilitates treatment initiation in patients with poor adherence. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 452-460.	1.9	7
151	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1485-1493.	3.7	7
152	Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. <i>Journal of Personalized Medicine</i> , 2022, 12, 239.	2.5	7
153	Heterozygous carriage of the alpha1-antitrypsin Z variant rs28929474 predisposes to the development of cirrhosis in the presence of alcohol misuse and non-alcohol-related fatty liver disease. <i>Journal of Hepatology</i> , 2017, 66, S177.	3.7	6
154	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. <i>Scientific Reports</i> , 2019, 9, 11674.	3.3	6
155	Dynamics of platelet count after sustained virologic response do not mirror those of hepatic venous pressure gradient. <i>Liver International</i> , 2020, 40, 988-989.	3.9	6
156	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , 2020, 52, 1473-1479.	0.9	6
157	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2569-2580.	4.3	6
158	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414.	1.0	5
159	The association of smoking with IGRA and TST results in HIV-1-infected subjects. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 709-716.	1.2	5
160	HCV Reinfection Incidence and Outcomes among HIV Infected MSM in Western Europe. <i>Journal of Hepatology</i> , 2016, 64, S138-S139.	3.7	5
161	Effectiveness of early TIPS implantation versus late TIPS versus standard endoscopic treatment for acute variceal bleeding in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, S694-S695.	3.7	5
162	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. <i>BMC Medicine</i> , 2020, 18, 336.	5.5	5

#	ARTICLE	IF	CITATIONS
163	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021, 11, 281.	2.5	5
164	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , 2021, 10, 48.	3.9	5
165	Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. <i>Liver International</i> , 2021, 41, 2954-2964.	3.9	5
166	Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0137096.	2.5	5
167	Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients. <i>PLoS ONE</i> , 2016, 11, e0145319.	2.5	5
168	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. <i>Platelets</i> , 2022, 33, 879-886.	2.3	5
169	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	2.3	5
170	Exclusion of Varices Via Transient Elastography Combined with Platelet Count According to the Baveno VI Guidelines can Only be Made for Large not Small Varices. <i>Journal of Hepatology</i> , 2016, 64, S283.	3.7	4
171	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2712-2718.	2.3	4
172	Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies. <i>Journal of Hepatology</i> , 2020, 73, S105.	3.7	4
173	Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 69-79.	3.4	4
174	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 421-431.	1.9	4
175	P0871 : Real life experience with interferon/ribavirin-free antiviral treatment in renal transplant recipients and endstage renal disease-patients on dialysis infected with hepatitis C virus. <i>Journal of Hepatology</i> , 2015, 62, S667.	3.7	3
176	Portal Hypertension after Liver Transplantation – Causes and Management. <i>Current Hepatology Reports</i> , 2019, 18, 59-66.	0.9	3
177	Author response to Letter to the Editor: “ABO, von Willebrand factor/Factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?” <i>Liver International</i> , 2020, 40, 1790-1791.	3.9	3
178	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. <i>Liver International</i> , 2021, 41, 2622-2634.	3.9	3
179	Effect of liver resection-induced increases in hepatic venous pressure gradient on development of postoperative acute kidney injury. <i>BMC Nephrology</i> , 2022, 23, 21.	1.8	3
180	P781 SPONTANEOUS CLEARANCE RATES INCREASE WITH HCV REINFECTION EPISODE IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM) INDEPENDENT OF HCV SUBTYPE. <i>Journal of Hepatology</i> , 2014, 60, S331.	3.7	2

#	ARTICLE	IF	CITATIONS
181	P1038 NEW QUALITY CRITERIA FOR TRANSIENT ELASTOGRAPHY CAN INCREASE THE PROPORTION OF VALID MEASUREMENTS WITH HIGH ACCURACY FOR DETECTION OF LIVER CIRRHOSIS AND PORTAL HYPERTENSION. Journal of Hepatology, 2014, 60, S421.	3.7	2
182	Nonselective beta blockers in patients with ascites: implications of a nationwide study. Liver International, 2016, 36, 1255-1257.	3.9	2
183	Letter: sustained virological response and liver healing – authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1173-1174.	3.7	2
184	The novel point shear-wave elastography method ElastPQ Â® is accurate for non-invasive evaluation of liver fibrosis and portal hypertension. Journal of Hepatology, 2017, 66, S674.	3.7	2
185	Resolution of clinically significant portal hypertension after sustained virologic response to interferon-free regimens prevents hepatic decompensation. Journal of Hepatology, 2018, 68, S532.	3.7	2
186	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. Hepatology Communications, 2022, 6, 621-632.	4.3	2
187	Angiotensin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. Digestive and Liver Disease, 2022, 54, 1222-1229.	0.9	2
188	Reply. Gastroenterology, 2014, 147, 942.	1.3	1
189	O094 : The presence of echocardiographic abnormalities increases mortality in patients with spontaneous bacterial peritonitis. Journal of Hepatology, 2015, 62, S241-S242.	3.7	1
190	P0212 : Identifying the trigger matters – outcome of severe acute kidney injury in patients with cirrhosis and ascites. Journal of Hepatology, 2015, 62, S385.	3.7	1
191	P0783 : Viral kinetics during interferon-free sofosbuvir containing treatment regimens in a real-life cohort of chronic hepatitis C patients with advanced liver disease. Journal of Hepatology, 2015, 62, S625.	3.7	1
192	Letter: can persisting liver stiffness indicate increased risk for HCC, after successful anti-HCV therapy? - authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 43, 544-545.	3.7	1
193	The Evolution of Portal Pressure after Viral Suppression with Interferon-Free Therapies and its Correlation with the Change in Liver Stiffness. Journal of Hepatology, 2016, 64, S138.	3.7	1
194	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. Wiener Klinische Wochenschrift, 2016, 128, 414-420.	1.9	1
195	Multi-center study of liver disease in alpha1-antitrypsin deficiency: non-invasive evaluation of liver fibrosis in homozygous PiZZ patients. Journal of Hepatology, 2017, 66, S176-S177.	3.7	1
196	Editorial: use of beta-blockers and band ligation in preventing first and recurrent variceal bleeding – evidence-based decisions. Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1224-1225.	3.7	1
197	Role of alpha-1 antitrypsin genotypes in the progression of adult liver disease. Journal of Hepatology, 2018, 68, S618.	3.7	1
198	Role of diuretics in the harmful effects of beta blockers in patients with ascites. Authors' reply. Digestive and Liver Disease, 2018, 50, 102-103.	0.9	1

#	ARTICLE	IF	CITATIONS
199	Liver fibrosis and metabolic alterations in adults with homozygous alpha1-antitrypsin deficiency (PiZZ) Tj ETQq1 1 0.784314 1gBT /Over	3.7	1
200	Effect of vardenafil on portal hemodynamics in patients with mild and moderate liver dysfunction: a randomized, placebo-controlled trial. Journal of Hepatology, 2018, 68, S717.	3.7	1
201	High efficacy of IFN-free DAA therapy for acute HCV infection in HIV patients. Journal of Hepatology, 2018, 68, S273.	3.7	1
202	Impact of SVR to IFN-free DAA therapy on steatosis in HIV/HCV coinfecting patients. Journal of Hepatology, 2018, 68, S548.	3.7	1
203	Editorial: von Willebrand factor and CRP levels may predict survival in liver cirrhosisâ€”Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1537-1538.	3.7	1
204	SAT-114-Impact of farnesoid X receptor polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. Journal of Hepatology, 2019, 70, e680.	3.7	1
205	PS-067-Increasing incidence of HCV-GT2 as well as reinfections within the ongoing epidemic of acute HCV infections among MSM in Central Europe. Journal of Hepatology, 2019, 70, e40-e41.	3.7	1
206	FRI-255-Dynamics of HCV epidemiology among HIV+ patients in Vienna. Journal of Hepatology, 2019, 70, e506-e507.	3.7	1
207	Editorial: pressure to close the therapeutic window of nonâ€”selective beta blockers?. Alimentary Pharmacology and Therapeutics, 2019, 50, 957-958.	3.7	1
208	PS-186-Functional liver imaging score derived from gadoxetic acid-enhanced MRI predicts outcomes in patients with advanced chronic liver disease. Journal of Hepatology, 2019, 70, e115.	3.7	1
209	Sustained virologic response to direct-acting antivirals does affect the risk of portal vein thrombosis in patients with advanced chronic liver disease. Journal of Hepatology, 2020, 73, S619-S620.	3.7	1
210	Letter to the Editor: Perioperative Presentation of COVIDâ€”19 in a Liver Transplant Recipient. Hepatology, 2021, 73, 868-869.	7.3	1
211	Aro-Aat Reduces Z-AAT Protein in Pizz Patients and Leads to Improvements in Clinically Relevant Liver Biomarkers. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	1
212	VWF-response to NSBB-therapy â€” worth to re-read!. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	1
213	Intraperitoneal Activation of Blood Coagulation via Tissue Factor Exposing Extracellular Vesicles in Patients with Liver Disease and Ascites. Hamostaseologie, 2019, 39, .	1.9	1
214	907 LOW VITAMIN D SERUM LEVELS ARE ASSOCIATED WITH LIVER FIBROSIS AND IMPAIRED VIROLOGIC RESPONSE TO ANTIVIRAL THERAPY WITH PEGIFN+RBV IN HIV/HCV COINFECTED PATIENTS. Journal of Hepatology, 2012, 56, S353.	3.7	0
215	84 IMPROVEMENT OF INTESTINAL PERMEABILITY AND REDUCING BACTERIAL TRANSLOCATION BY BETABLOCKER TREATMENT IS ASSOCIATED WITH A LOWER RISK OF VARICEAL BLEEDING. Journal of Hepatology, 2013, 58, S37.	3.7	0
216	354 PREVALENCE OF AND RISK FACTORS FOR COMBINED cART ASSOCIATED DRUG-INDUCED LIVER INJURY IN HIV/HBV COINFECTED, HIV/HCV COINFECTED, AND HIV MONOINFECTED PATIENTS. Journal of Hepatology, 2013, 58, S147.	3.7	0

#	ARTICLE	IF	CITATIONS
217	860 REVISITING PREDICTORS OF VIROLOGIC RESPONSE TO PEGIFN+RBV THERAPY IN HIV/HCV COINFECTED PATIENTS: THE ROLE OF METABOLIC FACTORS AND ELEVATED GGT LEVELS. <i>Journal of Hepatology</i> , 2013, 58, S352-S353.	3.7	0
218	475 THE INFLUENCE OF PORTAL PRESSURE ON THE DISCORDANCE OF ABSOLUTE CD4+ COUNT AND CD4+ PERCENTAGE IN HIV/HCV COINFECTED PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S194-S195.	3.7	0
219	P954 PROTON PUMP INHIBITOR TREATMENT IS NEITHER ASSOCIATED WITH SPONTANEOUS BACTERIAL PERITONITIS DEVELOPMENT NOR WITH MORTALITY IN CIRRHOTIC PATIENTS WITH ASCITES. <i>Journal of Hepatology</i> , 2014, 60, S393.	3.7	0
220	P504 HEMODYNAMIC RESPONSE TO NON-SELECTIVE BETA BLOCKERS DESPITE LACK OF EFFECTS ON HEART RATE AND SYSTEMIC BLOOD PRESSURE. <i>Journal of Hepatology</i> , 2014, 60, S237.	3.7	0
221	O76 THE OCCURRENCE OF SPONTANEOUS BACTERIAL PERITONITIS CLOSES THE THERAPEUTIC WINDOW OF OPPORTUNITY FOR NON-SELECTIVE BETA BLOCKER TREATMENT IN CIRRHOTIC PATIENTS WITH ASCITES. <i>Journal of Hepatology</i> , 2014, 60, S31-S32.	3.7	0
222	P0884 : Interferon and ribavirin-free therapy with sofosbuvir and daclatasvir in a real-life cohort of difficult-to-treat HIV/HCV-coinfected patients with and without portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, S673-S674.	3.7	0
223	P0191 : IFN-free regimens overcome the negative effect of portal hypertension on virologic response and viral kinetics in patients with cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S376.	3.7	0
224	P0385 : Prognostic impact of the Baveno IV staging system of portal hypertension in patients with cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, S457.	3.7	0
225	P0208 : Hemodynamic response to non-selective beta-blockers is not influenced by the presence of metabolic syndrome. <i>Journal of Hepatology</i> , 2015, 62, S383-S384.	3.7	0
226	P0218 : Factors associated with hemodynamic response to propranolol and carvedilol in cirrhotic patients. <i>Journal of Hepatology</i> , 2015, 62, S388.	3.7	0
227	P0717 : The presence of a PNPLA3 (rs738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients. <i>Journal of Hepatology</i> , 2015, 62, S593.	3.7	0
228	P0740 : Usefulness of interferon LAMBDA4, HLA class II-polymorphism and killer-immunglobulin -like receptor-2DL3:C1/C1 to predict spontaneous clearance of acute hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 62, S602-S603.	3.7	0
229	O019 : The value of different non-invasive tests for predicting the presence of clinically significant portal hypertension and esophageal varices in cirrhotic patients. <i>Journal of Hepatology</i> , 2015, 62, S200.	3.7	0
230	Liver Stiffness Assessed by Transient Elastography can not Predict the Hemodynamic Response to Non-Selective Betablockers. <i>Journal of Hepatology</i> , 2016, 64, S287-S288.	3.7	0
231	Interferon-Free Daa Regimens Decrease Portal Pressure and Halt Histological Necroinflammation in HIV/HCV coinfectd Patients. <i>Journal of Hepatology</i> , 2016, 64, S623.	3.7	0
232	Interferon-Free Treatment with Sofosbuvir Plus Daclatasvir Achieves Sustained Virologic Response in 100% of Difficult-To-Treat HIV/HCV-Coinfectd Patients and Decreases Liver Stiffness. <i>Journal of Hepatology</i> , 2016, 64, S796-S797.	3.7	0
233	Von Willebrand factor antigen predicts portal hypertensive bleeding, infections, and survival, independently of portal hypertension severity. <i>Journal of Hepatology</i> , 2017, 66, S373-S374.	3.7	0
234	Reply to: â€œBeta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?â€. <i>Journal of Hepatology</i> , 2017, 67, 880-881.	3.7	0

#	ARTICLE	IF	CITATIONS
235	Editorial: direct acting antivirals - not the be-all and end-all in HIV/HCV co-infection. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 570-571.	3.7	0
236	Bacterial infections in cirrhosis – a retrospective analysis updating on microbiology and resistance rates. <i>Journal of Hepatology</i> , 2017, 66, S577.	3.7	0
237	Reply to: “Non selective beta blockers in cirrhosis” <i>Journal of Hepatology</i> , 2017, 67, 1343-1344.	3.7	0
238	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. <i>Journal of Hepatology</i> , 2018, 68, S730-S731.	3.7	0
239	Editorial: surviving your genes – the role of <i>PNPLA3</i> variation in end-stage liver disease. Authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 775-776.	3.7	0
240	Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience. <i>Journal of Hepatology</i> , 2018, 68, S729-S730.	3.7	0
241	Alpha1-antitrypsin augmentation therapy is associated with an improvement in liver-related parameters in patientes with severe alpha1-antitrypsin-deficiency. <i>Journal of Hepatology</i> , 2018, 68, S621-S622.	3.7	0
242	The impact of hepatic steatosis on portal hypertension. <i>Journal of Hepatology</i> , 2018, 68, S707.	3.7	0
243	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2018, 68, S707-S708.	3.7	0
244	Prevalence and resistance rates of infections with enterococci in patients with cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, S694.	3.7	0
245	PS-197-Heterozygous alpha-antitrypsin deficiency (Pi* <i>MZ</i>) is associated with increased liver stiffness and elevated liver enzymes in a multi-center European cohort. <i>Journal of Hepatology</i> , 2019, 70, e122.	3.7	0
246	SAT-486-Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e847.	3.7	0
247	PS-021-The development of portosystemic shunts depends on liver dysfunction rather than on PlGF-driven neoangiogenesis. <i>Journal of Hepatology</i> , 2019, 70, e16.	3.7	0
248	THU-230-HBV and HDV confection trends in HIV+ patients in Vienna. <i>Journal of Hepatology</i> , 2019, 70, e266.	3.7	0
249	SAT-020-Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites. <i>Journal of Hepatology</i> , 2019, 70, e633-e634.	3.7	0
250	THU-338-Prevalence and dynamics of NAFLD-associated fibrosis among. <i>Journal of Hepatology</i> , 2019, 70, e309.	3.7	0
251	PS-085-The impact of ABO blood group on von Willebrand factor levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e54.	3.7	0
252	SAT-117-Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension. <i>Journal of Hepatology</i> , 2019, 70, e681-e682.	3.7	0

#	ARTICLE	IF	CITATIONS
253	SAT-077-Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e661.	3.7	0
254	Clinical, histological, and biochemical liver phenotype of European adults with heterozygous alpha-1 antitrypsin deficiency (Pi* <i>MZ</i> genotype). <i>Journal of Hepatology</i> , 2020, 73, S547-S548.	3.7	0
255	Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies. <i>Journal of Hepatology</i> , 2020, 73, S608-S609.	3.7	0
256	Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, S697-S698.	3.7	0
257	Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, S736-S737.	3.7	0
258	Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response. <i>Journal of Hepatology</i> , 2020, 73, S743-S744.	3.7	0
259	Author response to Letter to the Editor: MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2021, 41, 221-222.	3.9	0
260	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.9	0
261	Populations-basierte Erfassung des Leberphänotyps bei Alpha1-Antitrypsinmangel. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.5	0
262	Author's reply to "Thromboelastometry in patients with advanced chronic liver disease: a complex interplay". <i>Hepatology International</i> , 2021, 15, 522-524.	4.2	0
263	This Letter to the Editor is in response to: "Non-hemodynamic effects of beta-blockers in decompensated cirrhosis: In search of an ideal marker"/corresponding author Sanchit SHARMA, M.D. D.M./CGH-01733. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
264	Einfluss der Augmentationstherapie mit Alpha1-Antitrypsin auf den Leberphänotyp von Individuen mit klassischem Alpha1-Antitrypsin-Mangel (Genotyp Pi* <i>ZZ</i>). <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, .	0.5	0
265	Controlled attenuation parameter (CAP®) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
266	The impact of hepatic steatosis on portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
267	Prevalence and Resistance Rates of Infections with Enterococci in Patients with Cirrhosis. , 2018, 56, .		0
268	Limited diagnostic performance of controlled attenuation parameter for assessing hepatic steatosis in patients with advanced chronic liver disease and portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
269	Transjugular liver biopsy performed by Hepatologists trained in hepatic venous pressure gradient measurements is safe and provides important diagnostic and prognostic information. , 2018, 56, .		0
270	Gadoxetic acid enhanced MRI distinguishes advanced chronic liver disease patients with improving liver function after sustained virologic response and patients with persistent liver damage. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0

#	ARTICLE	IF	CITATIONS
271	High prevalence of dyslipidemia but insufficient statin use in patients with non-cirrhotic and cirrhotic liver disease. , 2018, 56, .		0
272	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. , 2018, 56, .		0
273	Intestinal Biofilms are an endoscopic Feature of Irretable Bowel Syndrome. , 2019, 57, .		0
274	HCV-Scenario over the last decade at the Medical University Vienna: 6023 viremic HCV(+) patients identified with an 'overestimated' number of 3499 patients potentially left to cure. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
275	The impact of ABO blood type on VWF and factor VIII levels and the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
276	Impact of farnesoid X receptor (FXR) polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. , 2019, 57, .		0
277	Reliability criteria for controlled attenuation parameter (CAP) for assessing hepatic steatosis using transient elastography. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
278	Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
279	Prevalence of and risk factors for anemia in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
280	The value of different CT-based methods for diagnosing sarcopenia and predicting mortality in patients with cirrhosis. , 2019, 57, .		0
281	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
282	Die Substitution mit Alpha1-Antitrypsin ist bei Patienten mit schwerem Alpha1-Antitrypsin-Mangel (Pi*ZZ-Genotyp) mit einer Verbesserung Leber-bezogener Parameter assoziiert. , 2019, 57, .		0
283	EuropÄische Studie: Heterozygoter Alpha-1-Antitrypsinmangel (Pi*MZ) fÄ¼hrt zu einem intermediÄren Leber-PhÄnotyp. , 2020, 58, .		0
284	Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.5	0
285	Epidemiology of fulminant hepatitis E cases in Vienna - an informative case series. Journal of Hepatology, 2020, 73, S853-S854.	3.7	0
286	Die Augmentation mit Alpha1-Antitrypsin assoziiert bei Patienten mit klassischem Alpha1-Antitrypsin-Mangel (Pi*ZZ-Genotyp) mit besseren Leber-Parametern. , 2020, 58, .		0
287	Die Therapie mit Alpha-1-Antitrypsin (AAT) assoziiert bei AAT-Mangel mit besseren Leber-bezogenen Parametern. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.5	0
288	Covered transjugular intrahepatic portosystemic shunt improves hypersplenism-associated cytopenia in cirrhosis. , 2021, 59, .		0

#	ARTICLE	IF	CITATIONS
289	Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease. , 2021, 59, .		0
290	Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced-chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
291	Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
292	Acute haemodynamic response to intravenous propranolol predicts decompensation and mortality in patients with cirrhosis. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
293	Risk evaluation for acute kidney injury and acute-on-chronic liver failure via a blood-based biomarker panel in patients with cirrhosis. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
294	Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
295	NSBB-associated VWF-decreases in decompensated cirrhosis indicate a reduced risk of further decompensation, ACLF, and death. , 2021, 59, .		0
296	The link between bacterial translocation, systemic inflammation, and circulatory dysfunction in cirrhosis. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
297	Safety and efficacy of direct oral anticoagulants (DOACs) in Budd-Chiari Syndrome (BCS) - an Austrian multicenter study. , 2021, 59, .		0
298	Antibiotic therapy is associated with worse outcome in patients with hepatocellular carcinoma treated with sorafenib. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
299	Immunoglobulin subtypes and complement levels exhibit distinct dynamics across advanced chronic liver disease stages and predict first or further decompensation. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
300	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. , 2021, 59, .		0
301	Reply. Hepatology, 2022, 75, 764-765.	7.3	0
302	Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
303	Covered TIPS improves renal function in patients with cirrhosis and ascites. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
304	The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
305	Increasing ACE activity in liver disease impacts on fibrinolysis and inflammation - a potential link to COVID-19. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0
306	Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.5	0

#	ARTICLE	IF	CITATIONS
307	Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology, 2022, , .	3.7	0